Literature DB >> 17652638

Heterogeneous staining for mismatch repair proteins during population-based prescreening for hereditary nonpolyposis colorectal cancer.

Natasha Watson1, Fabienne Grieu, Melinda Morris, Jennet Harvey, Colin Stewart, Lyn Schofield, Jack Goldblatt, Barry Iacopetta.   

Abstract

The aim of this study was to determine the frequency of microsatellite instability (MSI(+)) in tumors from a population-based series of young colorectal cancer patients and its correlation with the loss of expression of mismatch repair (MMR) proteins. The BAT-26 mononucleotide repeat was used to screen for MSI(+) in all colorectal cancers diagnosed in Western Australia throughout a 5-year period in patients <60 years of age. MSI(+) was found in 75 of 1003 (7.5%) cases, of which six contained a concomitant mutation in BRAF and were therefore excluded from further investigations as possible hereditary nonpolyposis colorectal cancer. Immunohistochemistry was used to evaluate expression of the four major MMR proteins (MLH1, MSH2, MSH6, and PMS2) in the remaining 69 MSI(+) tumors. Complete loss of MLH1 and PMS2 expression or of MSH2 and MSH6 expression was found in 35 (51%) and 17 (25%) cases, respectively, whereas other patterns of complete loss were observed in eight cases (12%). Eight tumors (12%) were initially recorded as showing normal expression, but on review seven were reclassified as having abnormal staining because of heterogeneous patterns of MMR loss. Three of these seven cases had previously been found to have germline mutations. Because of possible misinterpretation of heterogeneous immunohistochemistry staining for MMR protein loss, MSI testing is recommended as the initial screen for population-based detection of hereditary nonpolyposis colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17652638      PMCID: PMC1975100          DOI: 10.2353/jmoldx.2007.060162

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  35 in total

1.  Is it time to abandon microsatellite instability as a pre-screen for selecting families for mutation testing for mismatch repair genes?

Authors:  Gareth D Evans; Fiona Lalloo; Tony Mak; Doug Speake; James Hill
Journal:  J Clin Oncol       Date:  2006-04-20       Impact factor: 44.544

2.  Value of immunohistochemical detection of DNA mismatch repair proteins in predicting germline mutation in hereditary colorectal neoplasms.

Authors:  Jinru Shia; David S Klimstra; Khedoudja Nafa; Kenneth Offit; Jose G Guillem; Arnold J Markowitz; William L Gerald; Nathan A Ellis
Journal:  Am J Surg Pathol       Date:  2005-01       Impact factor: 6.394

3.  Re: Ward et al. Routine testing for mismatch repair deficiency in sporadic colorectal cancer is justified. J Pathol 2005;207:377-384.

Authors:  Jeremy R Jass
Journal:  J Pathol       Date:  2006-03       Impact factor: 7.996

4.  Tumours from MSH2 mutation carriers show loss of MSH2 expression but many tumours from MLH1 mutation carriers exhibit weak positive MLH1 staining.

Authors:  Elisabeth Mangold; Constanze Pagenstecher; Waltraut Friedl; Hans-Peter Fischer; Sabine Merkelbach-Bruse; Maike Ohlendorf; Nicolaus Friedrichs; Stefan Aretz; Reinhard Buettner; Peter Propping; Micaela Mathiak
Journal:  J Pathol       Date:  2005-12       Impact factor: 7.996

5.  Routine testing for mismatch repair deficiency in sporadic colorectal cancer is justified.

Authors:  Robyn Lynne Ward; Jenny Turner; Rachel Williams; Brita Pekarsky; Deborah Packham; Marija Velickovic; Alan Meagher; Terence O'Connor; Nicholas John Hawkins
Journal:  J Pathol       Date:  2005-12       Impact factor: 7.996

6.  Hereditary colorectal cancer in the general population: from cancer registration to molecular diagnosis.

Authors:  M P de Leon; M Pedroni; P Benatti; A Percesepe; C Di Gregorio; M Foroni; G Rossi; M Genuardi; G Neri; F Leonardi; A Viel; E Capozzi; M Boiocchi; L Roncucci
Journal:  Gut       Date:  1999-07       Impact factor: 23.059

7.  Immunohistochemistry for hMLH1 and hMSH2: a practical test for DNA mismatch repair-deficient tumors.

Authors:  V A Marcus; L Madlensky; R Gryfe; H Kim; K So; A Millar; L K Temple; E Hsieh; T Hiruki; S Narod; B V Bapat; S Gallinger; M Redston
Journal:  Am J Surg Pathol       Date:  1999-10       Impact factor: 6.394

8.  What is the best way to assess microsatellite instability status in colorectal cancer? Study on a population base of 462 colorectal cancers.

Authors:  C Chapusot; L Martin; P Laurent Puig; T Ponnelle; N Cheynel; A M Bouvier; D Rageot; P Roignot; P Rat; J Faivre; F Piard
Journal:  Am J Surg Pathol       Date:  2004-12       Impact factor: 6.394

9.  BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status.

Authors:  Wei Qi Li; Kazuyuki Kawakami; Andrew Ruszkiewicz; Graeme Bennett; James Moore; Barry Iacopetta
Journal:  Mol Cancer       Date:  2006-01-10       Impact factor: 27.401

10.  Development of a fluorescent multiplex assay for detection of MSI-High tumors.

Authors:  Jeffery W Bacher; Laura A Flanagan; Regenia L Smalley; Nadine A Nassif; Lawrence J Burgart; Richard B Halberg; Wael M Abdel Megid; Stephen N Thibodeau
Journal:  Dis Markers       Date:  2004       Impact factor: 3.434

View more
  29 in total

1.  SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T).

Authors:  Thomas G Papathomas; Lindsey Oudijk; Alexandre Persu; Anthony J Gill; Francien van Nederveen; Arthur S Tischler; Frédérique Tissier; Marco Volante; Xavier Matias-Guiu; Marcel Smid; Judith Favier; Elena Rapizzi; Rosella Libe; Maria Currás-Freixes; Selda Aydin; Thanh Huynh; Urs Lichtenauer; Anouk van Berkel; Letizia Canu; Rita Domingues; Roderick J Clifton-Bligh; Magdalena Bialas; Miikka Vikkula; Gustavo Baretton; Mauro Papotti; Gabriella Nesi; Cécile Badoual; Karel Pacak; Graeme Eisenhofer; Henri J Timmers; Felix Beuschlein; Jérôme Bertherat; Massimo Mannelli; Mercedes Robledo; Anne-Paule Gimenez-Roqueplo; Winand Nm Dinjens; Esther Korpershoek; Ronald R de Krijger
Journal:  Mod Pathol       Date:  2015-02-27       Impact factor: 7.842

2.  PCR versus immunohistochemistry for microsatellite instability.

Authors:  Wade S Samowitz; Russell Broaddus; Barry Iacopetta; Jack Goldblatt
Journal:  J Mol Diagn       Date:  2008-02-14       Impact factor: 5.568

Review 3.  Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology.

Authors:  Antonia R Sepulveda; Stanley R Hamilton; Carmen J Allegra; Wayne Grody; Allison M Cushman-Vokoun; William K Funkhouser; Scott E Kopetz; Christopher Lieu; Noralane M Lindor; Bruce D Minsky; Federico A Monzon; Daniel J Sargent; Veena M Singh; Joseph Willis; Jennifer Clark; Carol Colasacco; R Bryan Rumble; Robyn Temple-Smolkin; Christina B Ventura; Jan A Nowak
Journal:  J Mol Diagn       Date:  2017-02-06       Impact factor: 5.568

Review 4.  Application of molecular diagnostics for the detection of Lynch syndrome.

Authors:  Maria S Pino; Daniel C Chung
Journal:  Expert Rev Mol Diagn       Date:  2010-07       Impact factor: 5.225

5.  Evaluating Mismatch Repair/Microsatellite Instability Status Using Cytology Effusion Specimens to Determine Eligibility for Immunotherapy.

Authors:  Elizabeth M Jacobi; Gene Landon; Russell R Broaddus; Sinchita Roy-Chowdhuri
Journal:  Arch Pathol Lab Med       Date:  2020-03-30       Impact factor: 5.534

6.  A state-wide population-based program for detection of lynch syndrome based upon immunohistochemical and molecular testing of colorectal tumours.

Authors:  Lyn Schofield; Fabienne Grieu; Jack Goldblatt; Benhur Amanuel; Barry Iacopetta
Journal:  Fam Cancer       Date:  2012-03       Impact factor: 2.375

7.  Molecular Biomarkers for the Evaluation of Colorectal Cancer.

Authors:  Antonia R Sepulveda; Stanley R Hamilton; Carmen J Allegra; Wayne Grody; Allison M Cushman-Vokoun; William K Funkhouser; Scott E Kopetz; Christopher Lieu; Noralane M Lindor; Bruce D Minsky; Federico A Monzon; Daniel J Sargent; Veena M Singh; Joseph Willis; Jennifer Clark; Carol Colasacco; R Bryan Rumble; Robyn Temple-Smolkin; Christina B Ventura; Jan A Nowak
Journal:  Am J Clin Pathol       Date:  2017-02-03       Impact factor: 2.493

8.  Mismatch repair protein expression and colorectal cancer in Hispanics from Puerto Rico.

Authors:  Wilfredo E De Jesus-Monge; Carmen Gonzalez-Keelan; Ronghua Zhao; Stanley R Hamilton; Miguel Rodriguez-Bigas; Marcia Cruz-Correa
Journal:  Fam Cancer       Date:  2010-06       Impact factor: 2.375

9.  MSH6 immunohistochemical heterogeneity in colorectal cancer: comparative sequencing from different tumor areas.

Authors:  Wei Chen; Rachel Pearlman; Heather Hampel; Colin C Pritchard; Michael Markow; Christina Arnold; Deborah Knight; Wendy L Frankel
Journal:  Hum Pathol       Date:  2019-11-27       Impact factor: 3.466

10.  Immunohistochemistry and microsatellite instability analysis in molecular subtyping of colorectal carcinoma based on mismatch repair competency.

Authors:  Lin Yuan; Yayun Chi; Weixiang Chen; Xiaochen Chen; Ping Wei; Weiqi Sheng; Xiaoyan Zhou; Daren Shi
Journal:  Int J Clin Exp Med       Date:  2015-11-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.